However, the possibility of applying TRAIL in clinical cancer therapy should be performed with great caution due to the reported possible toxicity of TRAIL to primary human hepatocytes, especially in patients with a diseased liver [29, 33, 34]. This evidence concerns the gene TNFSF10 and cancer.